FAIRFIELD, N.J., Feb. 15 /PRNewswire-FirstCall/ -- Astralis Ltd. (BULLETIN BOARD: ASTR) today announced the appointment of Mr. James Sharpe as Chief Executive Officer.

"Mr. Sharpe has significant experience in managing drug development companies. His expertise in the areas of finance, emerging biotechnology, and healthcare will facilitate Astralis' financial and clinical goals," noted Dr. Jose O'Daly, Chairman and principal founder of Astralis.

Prior to joining Astralis, from 1999 to 2005, Mr. Sharpe served as President and founder of Ankyr Consulting, L.L.C, an independent consulting company focused on strategy, business development, finance, mergers, acquisitions and operations for healthcare and biotechnology companies. From 1991 to 2005, he founded or served as President or executive management of several biotechnology companies involved in drug discovery, drug delivery, vaccines and gene therapy.

Mr. Sharpe stated, "Astralis has a unique technology platform which stems from a fascinating discovery in the area of immune system disorders and skin diseases. Our continued goal at Astralis is to bring our first product candidate, Psoraxine(R) for the treatment of Psoriasis, to market, as well as to continue our research and product development efforts in our other target areas."

Mr. Sharpe has a B.S. in Chemistry from Union College, and a MBA in Marketing and Finance from the University of Rochester. He was a founding member of the Pennsylvania Biotechnology Association, where he served as President for two years (1990-1992) and was a member of the Board of Directors for eight years (1989-1997). He also served for three years (1993 to 1996) as a member of the Board of Governors of the Emerging Company Section of the Biotechnology Industry Association (BIO).

This press release is provided in good-faith by Chiltern Magazine Services Ltd ("CMS") as a service to users. Whilst every care is taken in sourcing and preparing material included here, any error or incorrect content cannot form the basis for any legal action against the site-owner. Users are advised to check the accuracy of any statements before relying upon them. Likewise, any forward-looking statements made by the author of the press release should be treated as such.

For full details, please email keithw@cmsinfo.com